Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer
Subjects will receive standard of care treatment for SCLC with added treatment of Cisplatin
injection via endobronchial ultrasound aided bronchoscopy a total of four times. Outcome
measurements of tumor growth and survival will be compared to subjects receiving standard of
care treatment only.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Solid tumor growth after completion of interventional bronchoscopies
The Organization for Research and Treatment of Cancer Response Evaluation Criteria in Solid Tumors (RECIST) system will be used to grade the response to therapy.
Michael A. Jantz, MD
University of Florida
United States: Institutional Review Board
|University of Florida||Gainesville, Florida 32610-0277|